Regeneron Pharmaceuticals stock price forecast: $588.98 support in focus as REGN slides 3.86%

Traders Union
All News
Financial News
Regeneron slides 3.86% to $611.01 today

Highlights

EYLEA HD sales surged 52% in Q1 2026, countering internal competition and supporting Regeneron's portfolio growth.
DUPIXENT performance and new FDA approvals for EYLEA HD and CEMDISIRAN diversify revenues and give near-term regulatory clarity.
REGN trades below major moving averages with momentum skewed bearish, and price is likely to fluctuate between $588.98 and $633.04; further downside risk is elevated.

Portfolio strength offsets internal pressures as institutional holders persist

U.S. sales of EYLEA HD surged 52% in the first quarter of 2026, signaling increased demand within Regeneron's core portfolio and helping mitigate the effects of internal product competition and patient switching, according to official reports. The period also saw robust growth from DUPIXENT, which has broadened the company's revenue stream and balanced exposure across flagship assets. Recent FDA approvals for EYLEA HD and CEMDISIRAN have provided additional regulatory certainty and near-term product catalysts, as noted by Seeking Alpha, while institutional investors and hedge funds retained a significant 83.31% ownership in the stock, per American Market News — though price action has remained under broader selling pressure.

Mixed momentum persists as shares breach key support levels

Specific technical levels indicate that REGN closed below its MA-20 at $628.03, MA-50 at $617.29, and well under MA-200 at $695.88. The immediate resistance stands at the Ichimoku Kijun level of $619.91. Momentum indicators present a mixed view: MACD signals a strong buy, while ADX points to selling conditions. The RSI at 39.95, together with oversold readings from Stoch RSI and CCI, underscores seller dominance. BBP is firmly in oversold territory, lending support to continued selling pressure. The Awesome Oscillator remains neutral after substantial high-volatility activity and a close near the day's low.

Downside risk prevails as trading range narrows amid volatility

Over the coming sessions, REGN is likely to trade within a typical volatility band stretching from $588.98 to $633.04. There is a 70% probability of continued downside movement and a 30% chance of a near-term reversal. The base-case scenario sees price action confined to this corridor, with a breakout above $619.91 resistance possibly signaling a bullish reversal, while a drop below $588.98 could accelerate further declines.

Anton Kharitonov, analyst at Traders Union, notes that Regeneron's positive Q1 sales and regulatory wins have not translated into bullish price action, with REGN sinking below key moving averages and closing at session lows. He points out that strong institutional ownership has not stemmed ongoing selling pressure, as technical signals and momentum readings stay decisively negative. The base case remains further downside within the $588.98 to $633.04 range unless price can reclaim the $619.91 resistance. "Current momentum and sentiment do not justify risk-on exposure until sustained recovery above key resistance is proven," Kharitonov concludes.

Earlier, analysts noted that Regeneron faced deepening downside momentum and heightened risk amid sustained technical weakness. The current combination of persistent selling pressure and mixed momentum signals suggests traders should monitor for a decisive move outside the $588.98 to $633.04 volatility band, as a breakout may set the stage for a directional shift.

Source of Data: REGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.